Showing results (1701-1710 of 2,176) with videos related to
Sort By:
Pageof 218
Clinical Genetics|November 15, 2000
Linkage exclusion and mutational analysis of the noggin gene in patients with fibrodysplasia ossificans progressiva (FOP)M Q Xu, G Feldman, M Le Merrer, et al.European Journal of Cancer (Oxford, England : 1990)|August 17, 2018
Pharmacogenetic analyses of 2183 patients with advanced colorectal cancer; potential role for common dihydropyrimidine dehydrogenase variants in toxicity to chemotherapyAyman Madi, David Fisher, Timothy S Maughan, et al.Nature|March 5, 2025
Sensory input, sex and function shape hypothalamic cell type developmentHarris S Kaplan, Brandon L Logeman, Kai Zhang, et al.Journal of Cellular Biochemistry|July 13, 2011
Substance P signaling mediates BMP-dependent heterotopic ossificationLixin Kan, Vitali Y Lounev, Robert J Pignolo, et al.Therapeutic Advances in Musculoskeletal Disease|December 22, 2025
Identifying global trends from case reports of fibrodysplasia ossificans progressiva: a scoping reviewChristiaan Scott, Mona Al Mukaddam, Michelle Davis, et al.Bone|July 25, 2017
Early clinical observations on the use of imatinib mesylate in FOP: A report of seven casesFrederick S Kaplan, Jeffrey R Andolina, Peter C Adamson, et al.Journal of Neurology|July 4, 2012
Neurological symptoms in individuals with fibrodysplasia ossificans progressivaJoseph A Kitterman, Jonathan B Strober, Lixin Kan, et al.Veterinary Microbiology|August 19, 2025
A modified-live Mannheimia haemolytica expressing Mycoplasma bovis EFTu and Hsp70 induced systemic and mucosal antibody responses in American bison but failed to fully protect against Mycoplasma bovis challengeBryan S Kaplan, Rohana P Dassanayake, Bradley O Chriswell, et al.Bone|June 18, 2026
Development of the Fibrodysplasia Ossificans Progressiva FLare EXperience Revised (FOP-FLEX-R©) Questionnaire: A patient-reported outcome measureRobert J Pignolo, Edward C Hsiao, Mona Al Mukaddam, et al.Blood Advances|January 4, 2018
Bortezomib-based antibody depletion for refractory autoimmune hematological diseasesSumita Ratnasingam, Patricia A Walker, Huy Tran, et al.Pageof 218